Trusted Resources: Education
Scientific literature and patient education texts
Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VII
source: Molecular genetics and metabolism reports
year: 2021
authors: Jones S,Coker M,López AG,Sniadecki J,Mayhew J,Hensman P,Jurecka A
summary/abstract:Vestronidase alfa is an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII). In this open-label, phase 1/2 study, three subjects with MPS VII received intravenous vestronidase alfa administered every other week (QOW) for 14 weeks (2 mg/kg), followed by 24-week forced-dose titration (1, 4, and 2 mg/kg QOW; 8 weeks each), 36-week continuation (2 mg/kg), and long-term extension (4 mg/kg). Vestronidase alfa was well tolerated and led to dose-responsive, sustained reductions in urinary glycosaminoglycan excretion.
organization: Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK.DOI: 10.1016/j.ymgmr.2021.100774
read more
Related Content
-
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and PatientsLysosomal storage diseases (LSDs) are in...
-
Enzyme Replacement Therapy With Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis o...Enzyme replacement therapy (ERT) improve...
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
-
Challenges of Enzyme Replacement Therapy for Sanfilippo SyndromeWhat Is Enzyme Replacement Therapy?Enzym...
-
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A SyndromeMucopolysaccharidosis type IVA (MPS IVA ...
-
Description of the Molecular and Clinical Characteristics of the Mucopolysaccharidosis Type VII Iberian CohortMucopolysaccharidosis type VII (Sly synd...
-
Therapy-Type Related Long-Term Outcomes in Mucopolysaccaridosis Type II (Hunter Syndrome) – Case SeriesMucopolysaccharidosis type II (MPS II, H...